A TUMOR GROWTH INHIBITION MODEL BASED ON M-PROTEIN LEVELS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING SINGLE-AGENT CARFILZOMIB USE

被引：0
|
作者：
Jonsson, F. [1 ]
Siegel, D. [2 ]
Jagannath, S. [3 ]
Vij, R. [4 ]
Badros, A. [5 ]
Ou, Y. [6 ]
Claret, L. [1 ]
Kavalerchik, E. [6 ]
Bruno, R. [1 ]
机构：
[1] Pharsight, St Louis, MO USA
[2] John Theurer Canc Ctr, Hackensack, NJ USA
[3] Mt Sinai Med Ctr, New York, NY 10029 USA
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[6] Onyx Pharmaceut Inc, San Francisco, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [1] A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use
    Jonsson, F.
    Ou, Y.
    Claret, L.
    Siegel, D.
    Jagannath, S.
    Vij, R.
    Badros, A.
    Aggarwal, S.
    Bruno, R.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2015, 4 (12): : 711 - 719
  • [2] Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
    Harvey, R. Donald
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2014, 6 : 87 - 96
  • [3] Management of Hematologic Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Nooka, Ajay K.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 11 - 18
  • [4] INCIDENCE AND MANAGEMENT OF CARDIAC AND PULMONARY ADVERSE EVENTS FOLLOWING SINGLE-AGENT CARFILZOMIB TREATMENT IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Richards, Tiffany
    [J]. ONCOLOGY NURSING FORUM, 2014, 41 (02) : E144 - E145
  • [5] Incidence and Management of Renal Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Shah, Jatin J.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 19 - 23
  • [6] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase ll trials
    Siegel, D.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lenial, S.
    [J]. ONKOLOGIE, 2013, 36 : 39 - 40
  • [7] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
    Siegel, D. S.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lonial, S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 20 - 20
  • [8] Overview and Management of Cardiac and Pulmonary Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Wang, Michael
    Cheng, Jie
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 24 - 30
  • [9] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Richardson, Paul
    Jagannath, Sundar
    Hussein, Mohamad
    Berenson, James
    Singhal, Seema
    Irwin, David
    Williams, Stephanie F.
    Bensinger, William
    Badros, Ashraf Z.
    Vescio, Robert
    Kenvin, Laurie
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome
    Knight, Robert
    Anderson, Kenneth C.
    [J]. BLOOD, 2009, 114 (04) : 772 - 778
  • [10] HEMATOLOGIC SAFETY PROFILE OF SINGLE-AGENT CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA FROM FOUR PHASE 2 STUDIES
    Nooka, A.
    [J]. HAEMATOLOGICA, 2012, 97 : 601 - 601
12345